DEA vs REGN · P/E 54, rev $302.1M vs P/E 14, rev $14.34B
Eerly Govt Ppty Inc (DEA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Eerly Govt Ppty Inc (DEA) is a reit - office company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DEA revenue for 2024-12-31 was $302.1M. Net income was $20.6M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. DEA currently screens at market cap $1.12B and trailing P/E 54.5.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DEA currently screens at market cap $1.12B and trailing P/E 54.5. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DEA and REGN stock pages for the full models.
Not investment advice.